GeneCentric Therapeutics

22 articles about GeneCentric Therapeutics

• GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

  4/1/2024

  GeneCentric Therapeutics today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

• GeneCentric Therapeutics Announces Upcoming Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium and Precision Medicine World Conference

  1/22/2024

  GeneCentric Therapeutics today announced upcoming presentations at the Precision Medicine World Conference (PMWC) in Santa Clara, California from January 24-26 and the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which will be held January 25-27 in San Francisco, California.

• GeneCentric Therapeutics Appoints Prasanth Reddy and Don Hardison to the Board of Directors as the Company Advances Its Oncology Diagnostics Pipeline

  11/14/2023

  GeneCentric Therapeutics today announced the appointment of Prasanth Reddy, MD, MPH, FACP, and Don Hardison as independent directors of its Board of Directors.

• GeneCentric Therapeutics Announces Publication of New Results Showing Clinical Benefit of RNA-based Antifolate Predictive Response Signature (AF-PRS) to Guide Lung Cancer Treatment Selection

  7/20/2023

  GeneCentric Therapeutics announced today the publication of initial results from the ongoing Piedmont study using real-world data in lung cancer to develop its novel RNA-based Antifolate Predictive Response Signature (AF-PRS), which is being co-developed as a clinical diagnostic test with Labcorp.

• GeneCentric Therapeutics Announces Commercial Availability of PurIST℠ Test for Pancreatic Cancer

  5/31/2023

  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that its PurIST℠ test is now commercially available through Tempus for clinical use.

• GeneCentric Therapeutics Initiates the Alamance Study – A Real-World Investigation of Bladder Cancer Patients Treated with FGFR Inhibitors and Other Standards of Care

  5/16/2023

  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the initiation of its Alamance study, a multi-center bladder cancer study conducted in collaboration with investigators at Memorial Sloan Kettering Cancer Center and the University of Wisconsin – Madison Carbone Cancer Center.

• GeneCentric Therapeutics Appoints Brian Kelly as SVP Business Development

  4/12/2023

  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development.

• GeneCentric to Present Data on the Purity Independent Subtyping of Tumor (PurIST℠) Test at AACR Pancreatic Conference

  9/13/2022

  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the poster presentation of further clinical validation data for PurIST℠, a novel RNA-expression test, in collaboration with Tempus.

• GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2

  8/23/2022

  GeneCentric Therapeutics announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 or IL-2 therapy and the development of a novel response classifier to IL-2 treatment.

• GeneCentric to Present Initial Clinicogenomic Results from the GARNER High-Risk Non-Muscle Invasive Bladder Cancer Real-World Study

  5/10/2022

  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American Urological Association (AUA) Annual Meeting, which is being held in New Orleans, Louisiana, May 13-16, 2022.

• GeneCentric to Present Discovery and Initial Clinical Utility of a Novel RNA-Based Gene Signature That Predicts Treatment Response in Patients With Head and Neck Cancer

  3/17/2022

  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral presentation of the discovery and initial clinical utility of a novel signature that identifies patients with head and neck squamous cell carcinoma (HNSCC) that may benefit from treatment beyond typical surgical resection.

• GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer

  12/21/2021

  GeneCentric Therapeutics announced today the completion of its Piedmont Study, conducted in collaboration with Atrium Health Levine Cancer Institute.

• GeneCentric Therapeutics Closes $7.5 Million Series B1 Financing

  11/8/2021

  GeneCentric Therapeutics today announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million.

• GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squamous Non-Small Cell Lung Cancer

  3/9/2021

  Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests

• GeneCentric Therapeutics Presents First Data on Novel Response Signatures to Treatment in Muscle Invasive Bladder Cancer (MIBC) Patients

  6/3/2019

  Data presented at 2019 ASCO Annual Meeting

• GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North Carolina

  9/24/2018

  Company will develop Pancreatic Cancer Profiler based on technology to identify drug responders for therapeutic development

• GeneCentric Therapeutics Appoints Michael V. Milburn, PhD, Chief Scientific Officer

  9/10/2018

  Dr. Milburn has more than 25 years of R&D successful leadership experience in biotechnology companies and in a major pharmaceutical company.

• GeneCentric Therapeutics to Present First Data on Cancer Subtyping Platform for Bladder Cancer, Potential for Use as Drug Response Biomarker

  5/30/2018

  Data to Be Presented at 2018 ASCO Annual Meeting

• Bristol-Myers Squibb And GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

  1/6/2017

• GeneCentric Diagnostics To Present Data At The 16th World Conference On Lung Cancer

  9/4/2015